US Needed Simple Pragmatic COVID-19 Trial For Repurposing Candidates, Woodcock Says

One such trial is being developed, but was needed early in the pandemic to answer many lingering questions about potential COVID-19 treatments.

Janet Woodcock, John Farley, Sally Seymour of FDA speak with AMA President Susan Bailey.
(Clockwise from bottom right) Acting Commissioner Janet Woodcock, Office of Infectious Disease Director John Farley and Division of Pulmonology, Allergy, Critical Care Director Sally Seymour, and AMA President Susan Bailey discussed COVID-19 therapeutics during an AMA webinar. • Source: screenshot

One of Janet Woodcock’s lessons learned from the coronavirus pandemic was that a simple clinical trial to test repurposed medications was necessary earlier to answer questions that are still lingering one year later.

Woodcock, the US Food and Drug Administration’s acting commissioner, said that she wished that while working on therapeutic development for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Clinical Trials

More from R&D

  • India Tightens Oversight Of CROs With Mandatory Registration

     
    • By 

    Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

  • Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

     
    • By 

    The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

  • How To Decarbonize Pharma R&D

     

    As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.